会计年度:2021-12-31收入分布
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 | ||||
| 合计 | 2,168,765,205.74 | 432,415,247.37 | 1,736,349,958.37 | 80.06 | ||||
| 化学合成药 | 134,646,083.73 | 99,630,747.36 | 35,015,336.37 | 26.01 | ||||
| 技术服务 | 94,639,087.13 | 49,409,378.47 | 45,229,708.66 | 47.79 | ||||
| 其他 | 63,025,693.29 | 35,406,149.64 | 27,619,543.65 | 43.82 | ||||
| 生物制品 | 1,295,157,406.40 | 150,509,638.44 | 1,144,647,767.96 | 88.38 | ||||
| 原料药 | 62,561,653.06 | 29,559,471.52 | 33,002,181.54 | 52.75 | ||||
| 中成药 | 518,735,282.13 | 67,899,861.94 | 450,835,420.19 | 86.91 | ||||
会计年度:2021-06-30
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 | ||||
| 合计 | 969,244,427.88 | 183,484,424.27 | 785,760,003.61 | 81.07 | ||||
| 化学合成药 | 66,123,765.54 | 49,726,853.28 | 16,396,912.26 | 24.80 | ||||
| 技术服务 | 19,767,515.20 | 10,694,662.57 | 9,072,852.63 | 45.90 | ||||
| 其他(补充) | 2,553,269.99 | 1,833,163.17 | 720,106.82 | 28.20 | ||||
| 生物制品 | 588,007,401.92 | 68,399,288.94 | 519,608,112.98 | 88.37 | ||||
| 原料药 | 26,757,285.77 | 11,045,299.47 | 15,711,986.30 | 58.72 | ||||
| 中成药 | 242,228,838.68 | 32,374,783.99 | 209,854,054.69 | 86.63 | ||||
会计年度:2020-12-31
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 | ||||
| 合计 | 1,701,417,216.20 | 361,080,412.08 | 1,340,336,804.12 | 78.78 | ||||
| 化学合成药 | 126,253,019.82 | 93,625,622.99 | 32,627,396.83 | 25.84 | ||||
| 技术服务 | 117,803,322.32 | 58,954,556.29 | 58,848,766.03 | 49.96 | ||||
| 其他 | 46,461,118.80 | 20,125,896.82 | 26,335,221.98 | 56.68 | ||||
| 生物制品 | 895,376,244.39 | 104,630,984.71 | 790,745,259.68 | 88.31 | ||||
| 原料药 | 59,256,241.73 | 23,367,236.85 | 35,889,004.88 | 60.57 | ||||
| 中成药 | 456,267,269.14 | 60,376,114.42 | 395,891,154.72 | 86.77 | ||||
会计年度:2020-06-30
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 | ||||
| 合计 | 712,025,492.29 | 138,573,749.57 | 573,451,742.72 | 80.54 | ||||
| 化学合成药 | 59,197,584.09 | 43,837,921.47 | 15,359,662.62 | 25.95 | ||||
| 技术服务 | 15,672,241.79 | 6,926,277.03 | 8,745,964.76 | 55.81 | ||||
| 生物制品 | 380,126,032.30 | 38,791,242.97 | 341,334,789.33 | 89.80 | ||||
| 原料药 | 36,233,455.70 | 13,561,443.74 | 22,672,011.96 | 62.57 | ||||
| 中成药 | 205,079,586.91 | 29,770,266.95 | 175,309,319.96 | 85.48 | ||||
会计年度:2019-12-31
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 | ||||
| 合计 | 1,712,529,669.21 | 376,213,484.32 | 1,336,316,184.89 | 78.03 | ||||
| 化学合成药 | 126,878,103.40 | 91,171,067.46 | 35,707,035.94 | 28.14 | ||||
| 技术服务 | 131,829,835.79 | 76,125,943.32 | 55,703,892.47 | 42.25 | ||||
| 其他 | 24,807,534.28 | 13,540,582.43 | 11,266,951.85 | 45.42 | ||||
| 生物制品 | 861,158,130.02 | 100,180,578.14 | 760,977,551.88 | 88.37 | ||||
| 原料药 | 77,683,666.84 | 27,437,997.97 | 50,245,668.87 | 64.68 | ||||
| 中成药 | 490,172,398.88 | 67,757,315.00 | 422,415,083.88 | 86.18 | ||||
1/5 转到 
违法和不良信息举报电话：010-85650899 传真：010-85650844 邮箱：yhts@staff.hexun.com
Copyright©和讯网 北京和讯在线信息咨询服务有限公司 All Rights Reserved 版权所有 复制必究 京ICP备10021077号
Copyright©和讯网 北京和讯在线信息咨询服务有限公司 All Rights Reserved 版权所有 复制必究 京ICP备10021077号